PMID-31702883 – Difelikefalin Phase 3 KALM-1 Hemodialysis Pruritus
Fishbane S, Jamal A, Engel B, et al. "A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus," N Engl J Med, 2020;382(3):222-232.
Quick Reference
| Property | Value |
|---|---|
| PMID | 31702883 |
| DOI | 10.1056/NEJMoa1912770 |
| Year | 2020 |
| Journal | New England Journal of Medicine |
| Study Type | Randomized Controlled Trial (Phase III) |
| Evidence Level | I |
| Sample | n=378 hemodialysis patients with moderate-to-severe pruritus |
| Peptide(s) Studied | Difelikefalin |
Key Findings
- Difelikefalin significantly reduced pruritus intensity: 49.1% of patients achieved >=3-point improvement on Worst Itching Intensity NRS vs 27.9% for placebo (P<0.001)
- Significant improvement in itch-related quality of life (Skindex-10, 5-D Itch Scale)
- Therapeutic effect observed as early as Week 1 and maintained through Week 12
- No evidence of CNS opioid effects (no euphoria, no respiratory depression, no drug-seeking behavior)
- Most common adverse events: diarrhea, dizziness, nausea (generally mild-to-moderate)
- No evidence of physical dependence on abrupt withdrawal
- This KALM-1 trial was pivotal for FDA approval of difelikefalin (Korsuva) in 2021
Study Design
Multicenter, randomized, double-blind, placebo-controlled Phase III trial (KALM-1). Hemodialysis patients with moderate-to-severe pruritus (WI-NRS >=5) randomized 1:1 to IV difelikefalin 0.5 mcg/kg or placebo administered at the end of each hemodialysis session (3x/week) for 12 weeks. Primary endpoint: proportion with >=3-point improvement in weekly mean WI-NRS at Week 12.
Limitations
- 12-week double-blind phase; long-term data from open-label extension
- Only IV formulation tested (oral formulation in separate development)
- Specific to CKD-associated pruritus in hemodialysis patients
- Moderate placebo response rate (27.9%)
- Excludes non-dialysis CKD patients
Clinical Relevance
This NEJM-published trial established difelikefalin as the first FDA-approved treatment specifically for CKD-associated pruritus, addressing a condition affecting 40-70% of hemodialysis patients with no prior approved therapy. The peripheral kappa-opioid receptor mechanism represents a paradigm shift — achieving opioid-mediated benefit without CNS penetration. This "peripherally restricted" design principle is relevant beyond pruritus, suggesting potential for pain conditions where central opioid effects are undesirable. The absence of addiction, tolerance, and respiratory depression makes this a landmark in peptide-based therapeutic design.
Related
#research #RCT #evidence-level-I #difelikefalin #fda-approved